Osmetech’s CYP450 2C9 Test, Fluidigm EP1 Genotyping System | GenomeWeb
Osmetech has launched a genetic test for CYP450 2C9 drug metabolism. The test identifies polymorphisms in the CYP2C9 gene, which the company said is associated with the metabolism of 10 percent of all drugs, including non-steroidal anti-inflammatory drugs, anticoagulants, anti-epileptic agents, cholesterol-lowering drugs, and anti-diabetic agents.
 
The CYP2C9 test is available for research use only on the company’s eSensor XT-8 System. The company said it “may also seek FDA approval” for the test.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.